Profile data is unavailable for this security.
About the company
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
- Revenue in USD (TTM)274.10m
- Net income in USD-131.04m
- Incorporated2014
- Employees570.00
- LocationMaravai LifeSciences Holdings Inc10770 Wateridge Circle Suite 200Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 546-0004
- Fax+1 (302) 655-5049
- Websitehttps://www.maravai.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals Inc | 2.50bn | -168.69m | 2.06bn | 7.70k | -- | -- | 19.36 | 0.8263 | -0.5642 | -0.5642 | 11.52 | -0.2065 | 0.7046 | 2.94 | 4.11 | 324,059.50 | -3.40 | -4.80 | -4.27 | -5.93 | 35.28 | 34.76 | -4.82 | -9.00 | 0.97 | 1.27 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.06bn | 526.00 | -- | 1.99 | -- | 39.21 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.06bn | 383.00 | -- | 2.77 | -- | 70.17 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.07bn | 1.76k | 14.59 | 3.07 | 10.30 | 3.06 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.08bn | 55.00 | -- | 5.85 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Geron Corp | 520.00k | -201.40m | 2.11bn | 141.00 | -- | 6.04 | -- | 4,049.27 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.11bn | 1.54k | -- | -- | -- | 2.12 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.17bn | 61.00 | -- | 3.82 | -- | 4,028.08 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.18bn | 226.00 | -- | 35.32 | -- | 23.67 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.18bn | 570.00 | -- | 5.32 | -- | 7.97 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.19bn | 160.00 | -- | 2.62 | -- | 361.47 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.64 | -- | 12.63 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.21bn | 624.00 | -- | 14.40 | 464.22 | 7.82 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.27bn | 445.00 | -- | 3.71 | -- | 31.81 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.27bn | 16.00k | -- | 1.43 | -- | 0.7549 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Data as of Jun 06 2024. Currency figures normalised to Maravai LifeSciences Holdings Inc's reporting currency: US Dollar USD
47.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 12 West Capital Management LPas of 31 Mar 2024 | 13.20m | 9.98% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.88m | 7.47% |
| Braidwell LPas of 31 Mar 2024 | 7.22m | 5.46% |
| Millennium Management LLCas of 09 May 2024 | 7.13m | 5.39% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.18m | 3.92% |
| Mackenzie Financial Corp.as of 31 Mar 2024 | 5.02m | 3.79% |
| Marshall Wace LLPas of 31 Mar 2024 | 4.83m | 3.65% |
| Massachusetts Financial Services Co.as of 31 Mar 2024 | 3.95m | 2.99% |
| Point72 Asset Management LPas of 31 Mar 2024 | 3.61m | 2.73% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 3.21m | 2.43% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
